• Type: Glycopeptide antibiotic active against MRSA
  • Dosage Forms: IV
  • Common Trade Names: Vibativ

Adult Dosing

  • 10 mg/kg IV q24hr

Special Populations

  • Pregnancy Rating: C
  • Lactation: Unknown
  • Renal Dosing
    • CrCl 30-50 mL/minute: 7.5 mg/kg IV q24hr
    • CrCl 10-29 mL/minute: 10 mg/kg IV q48hr
    • Pediatric
  • Hepatic Dosing
    • Adult
    • Pediatric


  • Allergy to class/drug
  • Concomitant use of IV heparin

Adverse Reactions


  • Renal impairment
  • C. diff colitis
  • Prolonged QT


  • Nausea/vomiting, diarrhea, taste disturbance
  • Foamy urine
  • Dizziness
  • Rigors
  • Pruritus, rash


  • Half-life: 8hr
  • Metabolism:
  • Excretion: Urine
  • Mechanism of Action: Lipoglycopeptide antibiotic that is a synthetic derivative of vancomycin; inhibits bacterial cell wall synthesis by interfering with polymerization and cross-linking of peptidoglycan

Antibiotic Sensitivities[1]

Group Organism Sensitivity
Gram PositiveStrep. Group A, B, C, GS
Strep. PneumoniaeS
Viridans strepX1
Strep. anginosus gpX1
Enterococcus faecalisS
Enterococcus faeciumS
Staph. EpidermidisS
C. jeikeiumS
L. monocytogenesS
Gram NegativesN. gonorrhoeaeR
N. meningitidisR
Moraxella catarrhalisX1
H. influenzaeX1
E. coliR
Klebsiella spR
E. coli/Klebsiella ESBL+R
E coli/Klebsiella KPC+R
Enterobacter sp, AmpC negR
Enterobacter sp, AmpC posR
Serratia spX1
Serratia marcescensR
Salmonella spR
Shigella spR
Proteus mirabilisX1
Proteus vulgarisR
Providencia sp.X1
Morganella sp.X1
Citrobacter freundiiX1
Citrobacter diversusX1
Citrobacter sp.X1
Aeromonas spX1
Acinetobacter sp.R
Pseudomonas aeruginosaR
Burkholderia cepaciaR
Stenotrophomonas maltophiliaR
Yersinia enterocoliticaX1
Francisella tularensisX1
Brucella sp.R
Legionella sp.X1
Pasteurella multocidaX1
Haemophilus ducreyiX1
Vibrio vulnificusX1
MiscChlamydophila spX1
Mycoplasm pneumoniaeX1
Rickettsia spR
Mycobacterium aviumX1
Bacteroides fragilisR
Prevotella melaninogenicaR
Clostridium difficileS
Clostridium (not difficile)S
Fusobacterium necrophorumX1
Peptostreptococcus sp.S


  • S susceptible/sensitive (usually)
  • I intermediate (variably susceptible/resistant)
  • R resistant (or not effective clinically)
  • S+ synergistic with cell wall antibiotics
  • U sensitive for UTI only (non systemic infection)
  • X1 no data
  • X2 active in vitro, but not used clinically
  • X3 active in vitro, but not clinically effective for Group A strep pharyngitis or infections due to E. faecalis
  • X4 active in vitro, but not clinically effective for strep pneumonia


  1. Sanford Guide to Antimicrobial Therapy 2014
This article is issued from Wikem. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.